Subscribe
shutterstock_1197730855_photobyphm
photobyphm / Shutterstock.com
29 July 2019Big PharmaRory O'Neill

Pfizer off-patent division to merge with Mylan

Pfizer is to merge its off-patent drug business Upjohn with Mylan, in a deal that will see Pfizer shareholders own 57% of the new company.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

More on this story

Big Pharma
90% of essential medicines off-patent, study reveals
10 December 2020   Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.
Americas
Former FDA head takes place on Pfizer board
28 June 2019   Pfizer has appointed former US Food and Drug Administration commissioner Scott Gottlieb to its board.
Big Pharma
Pfizer to acquire Array BioPharma for $11.4bn
17 June 2019   US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.

More features

UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC